Efficacy of pneumococcal conjugate vaccine in preventing acquisition and carriage of pneumococcal vaccine serotypes in Tanzanian children withhuman immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS)

Prof Robert Booy0 sites216 target enrollmentNovember 17, 2010

ConditionsPneumococcal disease HIV/AIDS Public Health - Epidemiology Infection - Studies of infection and infectious agents

Overview

Phase: 未知
Intervention: Not specified
Conditions: Pneumococcal disease
Sponsor: Prof Robert Booy
Enrollment: 216
Status: Not yet recruiting
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

November 17, 2010

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Prof Robert Booy

Eligibility Criteria

Inclusion Criteria

•HIV positive children aged 1\-14 years old

Exclusion Criteria

•Previous vaccination

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Not Applicable

Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia

ISRCTN21541376Central Manchester and Manchester Children's Hospital (UK)97

Active, not recruiting

Phase 1

Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia - Pneumococcal conjugate vaccination in Haematology patients: Version 1Pneumococcal disease is a common form of meningitis, septicaemia and pneumonia. Those individuals at highest risk include children, the elderly and persons whose immune systems are impaired. This latter group is diverse includes patients with the haematological disorders myeloma and chronic lymphocytic leukaemia in whom infections are a leading cause of death.

EUCTR2005-003761-16-GBDepartment of R & D, Central Manchester and Manchester Children's Hospital NHS Trust97

Completed

Not Applicable

Inmunogenicity-PCV-Carriage-Venezuelan High Risk ChildreInfection Prophylaxis of Streptococcus pneumoniae

RPCEC00000150Servicio Autónomo Instituto de Biomedicina110

Active, not recruiting

Phase 1

Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. - Immunogenicity of Prevenar in Ataxia telangiectasia

EUCTR2005-004122-70-GBGreat Ormond Street Hospital30

Active, not recruiting

Not Applicable

The role of under-fives in pneumococcal transmission to newborn babies within households

ISRCTN10912262iverpool School of Tropical Medicine2,588